IKK2 Inhibitor VI
| Code | Size | Price |
|---|
| TAR-T36524-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T36524-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T36524-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Inhibitor of NF-κB kinase 2 (IKK2, also known as IKKβ) acts as part of an IKK complex in the canonical NF-κB pathway, phosphorylating inhibitors of NF-κB (IκBs) to initiate signaling. NF-κB signaling can also occur through a non-canonical, IKK/IκB-independent pathway. IKK2 Inhibitor VI is a potent, cell-permeable, reversible inhibitor of IKK2 (IC50 = 13 nM). [1] It is used to evaluate the role of the canonical, IκB-dependent NF-κB signaling pathway in cellular responses.[2][3]
CAS:
354811-10-2
Formula:
C12H11N3O2S
Molecular Weight:
261.3
Purity:
0.98
SMILES:
NC(=O)Nc1sc(cc1C(N)=O)-c1ccccc1
References
Punj, V., Matta, H., and Chaudhary, P.M. A computational profiling of changes in gene expression and transcription factors induced by vFLIP K13 in primary effusion lymphoma. PLoS One 7(5), 1-15 (2012).
McNamara, L.A., Ganesh, J.A., and Collins, K.L. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-?B activation. Journal of Virology 86(17), 9337-9350 (2012).
Baxter, A., Brough, S., Cooper, A., et al. Hit-to-lead studies: The discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorganic & Medicinal Chemistry Letters 14, 2817-2822 (2004).